Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERVAVAC in Women Living With HIV Aged 15-25 Years
NCT06281119Phase 3Active, not recruiting
- Sponsor
- Serum Institute of India
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of CERVAVAC in human papillomavirus infection, sponsored by Serum Institute of India. Started Oct 2025; status: active, not recruiting.
02
Drugs
CERVAVAC
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06281119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281119.